Sugammadex Sodium
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Sugammadex Sodium |
| DrugBank ID | DB06206 |
| Brand Names (EU) | Sugammadex Fresenius Kabi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.49% |
Approved Indication (EMA)
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | breast fibrocystic disease | 98.49% | DL |
| 2 | Prinzmetal angina | 98.39% | DL |
| 3 | peripheral arterial disease | 98.06% | DL |
| 4 | blunt duct adenosis of breast | 97.82% | DL |
| 5 | apocrine adenosis of breast | 97.82% | DL |
| 6 | thrombotic disease | 97.50% | DL |
| 7 | tendinitis | 97.42% | DL |
| 8 | antithrombin deficiency type 2 | 97.42% | DL |
| 9 | benign mammary dysplasia | 97.42% | DL |
| 10 | female breast carcinoma | 97.30% | DL |
| 11 | factor 5 excess with spontaneous thrombosis | 97.30% | DL |
| 12 | epiglottitis | 97.26% | DL |
| 13 | ischemic disease | 97.25% | DL |
| 14 | angiodysplasia | 97.22% | DL |
| 15 | idiopathic granulomatous myositis | 97.19% | DL |
| 16 | myositis fibrosa | 97.19% | DL |
| 17 | hemoglobinopathy | 97.17% | DL |
| 18 | fibrocartilaginous embolism | 97.12% | DL |
| 19 | venous thromboembolism | 97.12% | DL |
| 20 | breast adenosis | 97.09% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.